COLLEGE STATION, Texas, Nov. 3, 2025 /PRNewswire/ — Matica Biotechnology, Inc. has entered into a strategic partnership with Calidi Biotherapeutics, Inc. This collaboration will focus on the development of CLD-401, an oncolytic virus therapy targeting metastatic cancer sites. Under the agreement, Matica will provide analytical development, process development, and GMP manufacturing support for Calidi’s IND submission.
The CLD-401 candidate utilizes a tumor-tropic oncolytic virus designed to selectively infect tumor cells, induce immune responses, and deliver IL-15 superagonists to enhance anti-tumor activity. Matica’s facility in College Station, Texas,is equipped for complex viral vector manufacturing, supporting the development of this innovative treatment.
The partnership highlights Matica’s established reputation in the CDMO sector, particularly in oncolytic virus production, with experience successfully managing various related programs. Both companies express confidence in advancing cancer therapies through this collaboration.
Why it matters:
- The partnership may accelerate the development of new cancer immunotherapies, potentially leading to more effective treatment options for patients.
- For businesses involved in biotech, this collaboration signals the increasing importance of specialized CDMOs in advancing complex therapeutic developments.
The latest:
- The IND submission process for CLD-401 is currently underway, marking a significant step toward clinical trials.
Source: https://www.biospace.com/press-releases/matica-bio-a-cdmo-leader-in-oncolytic-virus-manufacturing-partners-with-calidi-biotherapeutics-to-advance-calidis-project-toward-ind
Source: https://www.biospace.com/press-releases/matica-bio-a-cdmo-leader-in-oncolytic-virus-manufacturing-partners-with-calidi-biotherapeutics-to-advance-calidis-project-toward-ind